New Paper Looks at Assessment of Risks and Benefits of Beta Cell Replacement Versus Automated Insulin Delivery Systems for Type 1 Diabetes

Diagram of Assessment of Risks and Benefits of Beta Cell Replacement Versus Automated Insulin Delivery Systems for Type 1 Diabetes

A figure from the publication.

 

A paper from Diabetes Action Canada researchers Drs. Peter Senior, Bruce Perkins and Remi Rabasa-Lhoret, along with Patient Partner Kate Farnsworth, was recently released in the journal Springer Nature.

The paper, Assessment of Risks and Benefits of Beta Cell Replacement Versus Automated Insulin Delivery Systems for Type 1 Diabetes, looks in detail at these treatment options.

Read the paper here.

 

 


Stay updated with News and Events